Trial Profile
A randomized trial of pivanex [AN 9] plus docetaxel or docetaxel monotherapy in patients with chemotherapy resistant advanced non-small cell carcinoma of the lung (NSCLC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Sep 2005
Price :
$35
*
At a glance
- Drugs AN 9 (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Sep 2005 New trial record.